Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, was quoted in the Bloomberg BNA Health Care Daily Report, in “Arizona Law Puts Pressure on FDA to Change Off-Label Policies,” by Bronwyn Mixter. (Read the full version – subscription required.)
Following is an excerpt:
“The state law can effectively remove state penalties, and that's what it's done. But it doesn't touch the federal requirements. They remain in place and the law of the land,” Bradley Merrill Thompson, a Washington-based health-care attorney with Epstein Becker & Green PC, told Bloomberg BNA in a March 29 email. “This really seems more of a symbolic act, than anything with practical effect.”